Basal Cell Carcinoma Pipeline, NDA Approvals, Clinical Trials Assessment 2023 (Updated) | Companies - AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, and others

DelveInsight's, "Basal Cell Carcinoma Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Basal Cell Carcinoma pipeline landscape. It covers the Basal Cell Carcinoma pipeline drug profiles, including Basal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Basal Cell Carcinoma Pipeline treatment landscape of the report, click here @ Basal Cell Carcinoma Pipeline Outlook- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Basal Cell Carcinoma Pipeline Report
• DelveInsight's Basal Cell Carcinoma Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma.
• The leading Basal Cell Carcinoma Companies include PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Promising Basal Cell Carcinoma Pipeline Therapies includes BF-200 ALA, methyl-aminolevulinate, Patidegib, LDE225B, imiquimod, Vismodegib, Metvix® cream, and others.
• In December 2022, MediWound Ltd., a highly integrated biopharma firm that focuses on next-generation cell therapy treatments for tissue repair and regeneration, published a Phase I/II trial to assess the safety and efficacy of MW005 in the therapy of low-risk skin malignancies.
• In December 2022: A major biopharmaceutical company in the investigation and development of RNAi therapeutics, Sirnaomics Ltd., published the interim data of part-one of an ongoing Phase IIb clinical study of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma in Situ (isSCC).

For further information, refer to the detailed Basal Cell Carcinoma Unmet Needs, Basal Cell Carcinoma Market Drivers, and Basal Cell Carcinoma Market Barriers, click here for Basal Cell Carcinoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Overview
Basal Cell Carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of Basal Cell Carcinoma.

Request a sample and discover the recent advances in Basal Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Basal Cell Carcinoma Treatment Landscape- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Emerging Drugs Profile

• Patidegib: PellePharm
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

• AIV001: AiViva BioPharma
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

Dive deep into rich insights for drugs for Basal Cell Carcinoma Market Drivers and Basal Cell Carcinoma Market Barriers, click here @ Basal Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Basal Cell Carcinoma. The companies which have their Basal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

Scope of the Basal Cell Carcinoma Pipeline Report
• Coverage- Global
• Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Basal Cell Carcinoma Pipeline Therapies- BF-200 ALA, methyl-aminolevulinate, Patidegib, LDE225B, imiquimod, Vismodegib, Metvix® cream, and others
• Basal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Got Queries? Find out the related information on Basal Cell Carcinoma Mergers and acquisitions, Basal Cell Carcinoma Licensing Activities @ Basal Cell Carcinoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Basal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Basal Cell Carcinoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Patidegib: PellePharm
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IO103: IO Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AIV001: AiViva BioPharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Leaf Vertical
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Basal Cell Carcinoma Key Companies
21. Basal Cell Carcinoma Key Products
22. Basal Cell Carcinoma- Unmet Needs
23. Basal Cell Carcinoma- Market Drivers and Barriers
24. Basal Cell Carcinoma- Future Perspectives and Conclusion
25. Basal Cell Carcinoma Analyst Views
26. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.